Human papilloma virus vaccination for the prevention of cervical and other related cancers

• Autores: Francesc Xavier Bosch José
• Localización: Anales (Reial Acadèmia de Medicina de la Comunitat Valenciana), ISSN-e 2172-8925, Nº. 12, 2011, 20 págs.
• Idioma: español
• Títulos paralelos:
  • Vacunación frente al virus del papiloma humano
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Academic research described in the late 1980´s the causal associ ation between human papillomavirus (HPV) and cervical cancer, la ter expanded to signifi cant fractions of all other genital tract cancers in both genders as well as a pr oportion of the cancers of the oral cavity and oropharynx. Prophylactic phase III HPV vaccine trials have shown complete type specific vaccine efficacy agai nst two HPV types, namely HPV 16 and 18, that together account for over 70% of cervi cal cancer worldwide.

    HPV vaccines have proven in trials to have an excellent safe try record. Most developed populations have introduced HPV vaccines as part of their routine vaccinat ion schemes and introduction into developing countries is being actively planned. In 2012, over 100 million vaccine doses have been delivered and records of continuous efficacy and safety are encouraging. Comprehensive strategies of HPV vaccination and HPV based screening tests could theoretically eliminate ce rvical cancer in de fined populations.